Search results for "IBA"

showing 10 items of 1355 documents

Les paradoxes de l'emploi féminin sur le pourtour méditérranéen

2012

Cette invitation originale à un voyage sur le pourtour de la Méditerranée permet de mieux appréhender les raisons de la colère des jeunes. L'analyse comparative dans quatorze pays révèle les paradoxes de l'emploi féminin dans des contextes sociaux, démographiques, culturels et économiques, plus ou moins distants, à la lumière de données statistiques les plus récentes. Ces contrées reflètent une image pessimiste : en écho d'une segmentation du marché du travail, le chômage frappe particulièrement la jeunesse, les itinéraires des jeunes femmes ressemblent à un dédale d'incertitudes et de contradictions. Pourtant, certains pays leur offrent davantage d'opportunités.

CroatieEmploi des femmesPalestineComparaison internationaleEmploi des jeunes[SHS.EDU]Humanities and Social Sciences/Education[SHS.EDU] Humanities and Social Sciences/EducationLibanSyrieTurquie[ SHS.EDU ] Humanities and Social Sciences/EducationTunisieMarocAlgérieBosnie-HerzégovineIsraëlAlbanieBassin méditerranéenMonténégroChômageÉgypteAnalyse comparativeJordanieMarché du travail
researchProduct

Proteomic analysis highlights the role of detoxification pathways in increased tolerance to Huanglongbing disease.

2016

Background Huanglongbing (HLB) disease is still the greatest threat to citriculture worldwide. Although there is not any resistance source in the Citrus germplasm, a certain level of moderated tolerance is present. A large-scale analysis of proteomic responses of Citrus may help: 1) clarifying physiological and molecular effects of disease progression, 2) validating previous data at transcriptomic level, and 3) identifying biomarkers for development of early diagnostics, short-term therapeutics and long-term genetic resistance. Results In this work we have conducted a proteomic analysis of mature leaves of two Citrus genotypes with well-known differing tolerances to HLB: Navel orange (highl…

Crop and Pasture Production0106 biological sciences0301 basic medicineProteomicsCitrusCandidatus LiberibacterProteomePlant Biology & BotanyCandidatus liberibacterPlant BiologyHuanglongbingPlant ScienceBiologyProteomicsMicrobiology01 natural sciencesTranscriptome03 medical and health sciencesCitrus Huanglongbing Candidatus liberibacter iTRAQ Proteome ProteomicRhizobiaceaeDetoxificationSettore AGR/07 - Genetica AgrariaGenotypePlant DiseasesGeneticsbusiness.industryProteomicbiology.organism_classificationCitrus; Huanglongbing; Candidatus liberibacter; iTRAQ; Proteome; ProteomicBiotechnologyMetabolic pathway030104 developmental biologyiTRAQProteomebusinessCitrus × sinensisMetabolic Networks and Pathways010606 plant biology & botanyCitrus sinensisResearch ArticleBMC plant biology
researchProduct

The influence of addition of Borago officinalis with antibacterial activity on the sensory quality of fresh pasta

2015

Abstract Borage (Borago officinalis L.) is a herbaceous plant of the Boraginaceae family cultivated throughout the world for several purposes, including food preparations, mainly beverages and salads. Some Italian recipes use borage as a food ingredient, in particular as condiment for pasta. The aqueous extract (AE) from borage leaves can act as biopreservative in foods due to its inhibition towards the main foodborne pathogen bacteria. Fresh pasta, due to the high content of water, is a food product with a limited shelf life. In order to test the suitability of borage to produce fresh pasta with a prolonged shelf life, borage AE was used in dried form as a raw material for the production o…

Cultural StudiesPreservativeFresh pastaFlavourSettore AGR/04 - Orticoltura E FloricolturaBorageShelf lifeIngredientFreshpastaFood scienceSensoryevaluationBorageSensory evaluationbiologyAqueous extractsBoraginaceaebiology.organism_classificationHorticultureAqueous extractAntibacterialactivityOfficinalisAqueous extracts;Antibacterialactivity;Borage;Freshpasta;SensoryevaluationBoragoAntibacterial activityFood ScienceSettore AGR/16 - Microbiologia AgrariaInternational Journal of Gastronomy and Food Science
researchProduct

Phytochemical Analysis and Cytotoxicity Towards Multidrug-Resistant Leukemia Cells of Essential Oils Derived from Lebanese Medicinal Plants

2012

Juniperus excelsa fruit essential oil as well as J. oxycedrus, Cedrus libani, and Pinus pinea wood essential oils have been obtained with yields between 2.2 ± 0.3 % to 3.4 ± 0.5 % and analyzed by gas chromatography. Sesquiterpenes mainly characterized C. libani and J. oxycedrus essential oils, while in P. pinea and J. excelsa, monoterpenes were the most abundant compounds. In J. oxycedrus, cis-calamenene (7.8 %), cuparene (3.8 %), and cis-thujopsenal (2.0 %) have been detected for the first time. The cytotoxic activity of these essential oils against drug-sensitive CCRF-CEM and multidrug-resistant P-glycoprotein-expressing CEM/ADR5000 leukemia cells has been investigated (IC₅₀ values: 29.46…

Cupressaceaegas chromatographyPharmaceutical ScienceAnalytical Chemistrylaw.inventionlawDrug DiscoveryTumor Cells CulturedLebanonMedicinal plantsLeukemiabiologyTraditional medicinePinaceaeWoodDrug Resistance MultiplePhytochemicalJuniperus excelsaPinaceaeMolecular MedicineSesquiterpenesJuniperus oxycedruscancer; essential oils; gas chromatography; multidrug resistance; Juniperus excelsa; Juniperus oxycedrus; Cupressaceae; Cedrus libani; Pinus pinea; PinaceaeNOmultidrug resistanceBotanyOils VolatileHumanscancerCedrusessential oilsEssential oilCedrus libaniPharmacologyPlants MedicinalOrganic ChemistryCupressaceaePinusbiology.organism_classificationCedrus libaniAntineoplastic Agents PhytogenicComplementary and alternative medicineDrug Resistance NeoplasmFruitJuniperusMonoterpenesPinus pineaJuniperus excelsaJuniperus oxycedrusPhytotherapyPlanta Medica
researchProduct

Propagation of three thymus species by stem cuttings

2006

Many herbs native to the Mediterranean region are grown for ornamental purposes and represent an important segment of the bedding plant industry. Although the majority of Thymus species are used as officinal plants, some of them are also used as ornamental bedding plants to provide aesthetic enhancement of public and private garden beds, porches, patios, balconies. The aim of this research was to study the vegetative propagation of T. capitatus, T. serpyllum and T. vulgaris. To verify the rooting response to exogenous application of auxin, softwood cuttings were either treated with a 500 ppm 1H-indol-3-butyric acid (IBA) solution, or not treated (control). Propagation was performed in an un…

CuttingfoodBotanyThymus vulgarisThymus capitatusThymus capitatus Thymus serpillum Thymus vulgaris propagation IBASettore AGR/04 - Orticoltura E FloricolturaHorticultureBiologybiology.organism_classificationfood.food
researchProduct

Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with…

2017

Summary Background We ran a compassionate use nationwide programme (ABACUS) to provide access to ombitasvir, paritaprevir, and ritonavir, with dasabuvir, plus ribavirin for hepatitis C virus (HCV) genotype 1 infection and ombitasvir, paritaprevir, and ritonavir, plus ribavirin for HCV genotype 4 infection in patients with cirrhosis at high risk of decompensation while approval of these regimens was pending in Italy. Methods In this prospective observational study, we collected data from a compassionate use nationwide programme from March 17, 2014, to May 28, 2015. Patients with HCV genotype 1 infection and cirrhosis at high risk of decompensation were given coformulated ombitasvir (25 mg), …

CyclopropanesCompassionate Use TrialsLiver CirrhosisMalechemistry.chemical_compound0302 clinical medicine2-NaphthylamineHCV direct-acting antiviral mixed cryoglobulinemia RBVAnilides030212 general & internal medicineLongitudinal StudiesProspective StudiesChronicAdult; Aged; Anilides; Antiviral Agents; Carbamates; Compassionate Use Trials; Drug Therapy Combination; Female; Genotype; Hepatitis C Chronic; Humans; Liver Cirrhosis; Longitudinal Studies; Macrocyclic Compounds; Male; Middle Aged; Prospective Studies; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; UracilSettore MED/12 - GastroenterologiaSulfonamidesDasabuvirHCV DAAGastroenterologyvirus diseasesValineMiddle AgedSettore MED/07 - Microbiologia e Microbiologia ClinicaHepatitis CTreatment OutcomeGastroenterology; HepatologyCombinationDrug Therapy Combination030211 gastroenterology & hepatologyFemalemedicine.drugAdultmedicine.medical_specialtyMacrocyclic CompoundsProlineGenotypeLactams MacrocyclicAdult; Aged; Anilides; Antiviral Agents; Carbamates; Compassionate Use Trials; Drug Therapy Combination; Female; Genotype; Hepatitis C Chronic; Humans; Liver Cirrhosis; Longitudinal Studies; Macrocyclic Compounds; Male; Middle Aged; Prospective Studies; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Hepatology; GastroenterologyHepatitis C virus genotype 1 Hepatitis C virus genotype 4 decompensated liver cirrhosis antiviral therapy dasabuvir ombitasvir paritaprevirHepatology; GastroenterologyAntiviral Agents03 medical and health sciencesDrug TherapyInternal medicineRibavirinmedicineHumansDecompensationAdverse effectUracilAgedRitonavirHepatologybusiness.industryRibavirinHepatitis C ChronicVirologyOmbitasvirClinical trialchemistryParitaprevirRitonavirCarbamatesbusiness
researchProduct

Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis

2018

Purpose: To analyse safety and efficacy of treatment based on ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in the sub-group of GT1 patients older than 65 years. Methods: We collected data extracted from the ABACUS compassionate-use nationwide Italian programme, in patients with cirrhosis due to hepatitis C virus (HCV) Genotype-1 (GT1) or 4 and at high risk of decompensation. GT1-HCV-infected patients received once-daily ombitasvir/paritaprevir, with the pharmacokinetic enhancer ritonavir (25/150/100 mg) and twice-daily dasabuvir (250 mg) plus Ribavirin (RBV) (OBV/PTV/r + DSV + RBV) for 12 (GT1b) or 24 (GT1a) weeks. Endpoints were to evaluate safety and efficacy, the latter def…

CyclopropanesLiver CirrhosisMaleCirrhosis;Dasabuvir;Elderly;Ombitasvir;ParitaprevirCirrhosis; Dasabuvir; Elderly; Ombitasvir; Paritaprevir; Aged; Aged; 80 and over; Anilides; Antiviral Agents; Biomarkers; Carbamates; Female; Hepacivirus; Hepatitis C; Chronic; Humans; Liver Cirrhosis; Macrocyclic Compounds; Male; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Drug Therapy; Combination; GenotypeParitaprevirCirrhosis Dasabuvir Elderly Ombitasvir Paritaprevir Microbiology (medical) Infectious DiseasesCirrhosis; Dasabuvir; Elderly; Ombitasvir; Paritaprevir; Aged; Aged 80 and over; Anilides; Antiviral Agents; Biomarkers; Carbamates; Female; Hepacivirus; Hepatitis C Chronic; Humans; Liver Cirrhosis; Macrocyclic Compounds; Male; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Drug Therapy Combination; Genotype; Microbiology (medical); Infectious DiseasesHepacivirusGastroenterologychemistry.chemical_compound0302 clinical medicineElderly2-Naphthylamine80 and overMedicineAnilides030212 general & internal medicineChronicAged 80 and overSulfonamidesDasabuvirValineGeneral MedicineHepatitis CHepatitis CTreatment OutcomeInfectious DiseasesCirrhosisCombination030211 gastroenterology & hepatologyDrug Therapy CombinationFemaleDasabuvirMacrocyclic CompoundCirrhosis; Dasabuvir; Elderly; Ombitasvir; Paritaprevir; Microbiology (medical); Infectious Diseasesmedicine.drugHumanMicrobiology (medical)medicine.medical_specialtyMacrocyclic CompoundsProlineGenotypeLactams MacrocyclicSettore MED/12 - GASTROENTEROLOGIALiver CirrhosiSulfonamideAntiviral Agents03 medical and health sciencesDrug TherapyInternal medicineRibavirinHumansDecompensationUracilAgedHepatitisAntiviral AgentCirrhosiHepaciviruRitonavirbusiness.industryRibavirinSettore MED/09 - MEDICINA INTERNAAnilideBiomarkerHepatitis C Chronicmedicine.diseaseCirrhosis; Dasabuvir; Elderly; Ombitasvir; Paritaprevir; Aged; Aged 80 and over; Anilides; Antiviral Agents; Biomarkers; Carbamates; Female; Hepacivirus; Hepatitis C Chronic; Humans; Liver Cirrhosis; Macrocyclic Compounds; Male; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Drug Therapy Combination; GenotypeOmbitasvirOmbitasvirchemistryParitaprevirCarbamateRitonavirCarbamatesbusinessBiomarkers
researchProduct

Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and…

2017

Background There is a need for hepatitis C virus (HCV) therapies with excellent efficacy across genotypes and in diverse populations. Part A of the C-CREST-1 and C-CREST-2 trials led to the selection of a three-drug regimen of grazoprevir (MK-5172; an HCV NS3/4A protease inhibitor; 100 mg/day) plus ruzasvir (MK-8408; an NS5A inhibitor; 60 mg/day) plus uprifosbuvir (MK-3682; an HCV NS5B polymerase inhibitor; 450 mg/day). Part B of the studies tested this combination as a single formulation in different treatment durations in a broader population. Methods Part B of these randomised, phase 2, open-label clinical trials enrolled individuals from 15 countries who were chronically infected with H…

CyclopropanesLiver CirrhosisMalePyrrolidinesSustained Virologic ResponseGastroenterologychemistry.chemical_compound0302 clinical medicinePegylated interferonGenotype030212 general & internal medicineSulfonamideseducation.field_of_studyGastroenterologyHepatitis CMiddle Aged10219 Clinic for Gastroenterology and HepatologyGrazoprevirHCVFemale030211 gastroenterology & hepatologymedicine.drugAdultmedicine.medical_specialtyGenotypePopulationFixed-dose combination610 Medicine & healthAntiviral AgentsHeterocyclic Compounds 4 or More RingsDrug Administration Schedule03 medical and health sciencesQuinoxalinesInternal medicineRibavirinmedicineHumans2715 GastroenterologyeducationUridinetherapyHepatologybusiness.industryRibavirinHepatitis C Chronicmedicine.diseaseAmidesThiazolesRegimenchemistryImmunology2721 HepatologyCarbamatesbusiness
researchProduct

Real-world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A met…

2017

The direct-acting antiviral regimen of ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) ± dasabuvir (DSV) ± ribavirin (RBV) demonstrated high rates of sustained viral response at post-treatment week 12 (SVR12) in clinical trials for treatment of hepatitis C virus (HCV) genotypes (GT) 1 and 4. To confirm the effectiveness of this regimen in the real world, we conducted meta-analyses of published literature on 30 April 2016. Freeman-Tukey transformation determined the SVR rate within GTs 1a, 1b, and 4, as well as specific SVR rates by cirrhosis or prior treatment experience status. Rates of virologic relapse, hepatic decompensation, drug discontinuation, and serious adverse events were also …

CyclopropanesLiver CirrhosisSustained Virologic ResponseHCV genotypes 1 and 4ComorbidityHepacivirusmedicine.disease_causeGastroenterologymeta-analysichemistry.chemical_compound0302 clinical medicineAnilides030212 general & internal medicineSulfonamidesDasabuvirValineHepatitis CViral LoadHepatitis Creal-world effectiveneInfectious DiseasesTreatment Outcome2D; 3D; HCV genotypes 1 and 4; hepatitis C; meta-analysis; real-world effectiveness; Hepatology; Infectious Diseases; Virology030211 gastroenterology & hepatologyDrug Therapy Combinationmedicine.drug3Dmedicine.medical_specialtyMacrocyclic CompoundsGenotypeProlineHepatitis C virusLactams MacrocyclicInfectious DiseaseAntiviral Agents03 medical and health sciencesInternal medicineVirologyRibavirinmedicineHumans2DRitonavirHepatologybusiness.industryRibavirinmedicine.diseaseOmbitasvirRegimenchemistryParitaprevirImmunologyRitonavirCarbamatesbusinessJournal of viral hepatitis
researchProduct

Efficacy of 8 weeks elbasvir/grazoprevir regimen for naïve-genotype 1b, HCV infected patients with or without glucose abnormalities: Results of the E…

2022

Background and aim: Direct Acting Antivirals(DAAs) achieve the highest rate of sustained viral re- sponse(SVR) in patients with genotype-1b(G1b) Hepatitis C virus(HCV) infection. Reducing treatment du- ration can simplify the management and improve adherence of therapy. Patients and methods: The study evaluates the efficacy of 8 weeks of elbasvir/grazoprevir regimen in 75 treatment-naïve(TN), G1b patients with mild-moderate fibrosis(Liver Stiffness by Fibroscan®< 9.0 kPa). Viral load(VL) has been evaluated by Roche TaqMan RT-PCR(LLOQ < 15 IU/ml). Results: Mean age was 61.0 ±14.2 years, 44% were male, mean LS by Fibroscan®was 6.1 ±1.8 kPa. Twenty-eight patients(37.3%) had an HOMA > …

CyclopropanesMalemedicine.medical_specialtyElbasvirGenotypeHepatitis C virusHepacivirusmedicine.disease_causeGastroenterologyAntiviral AgentsSettore MED/07Insulin resistanceFibrosisInternal medicineQuinoxalinesRibavirinmedicineElbasvir GrazoprevirHumansAgedBenzofuransSulfonamidesHepatologybusiness.industryGastroenterologyImidazolesHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseAmidesHepatitis CSustained virological responseRegimenGlucoseGrazoprevirHCVRNADrug Therapy CombinationFemaleCarbamatesSafetyLiver stiffnessbusinessDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct